-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013;33:215-23. pdf -
Maternal serum retinol-binding protein-4 at 11-13weeks' gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013;62:814-9. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction.
Ong CY, Liao AW, Munim S, Spencer K, Nicolaides KH.
J Matern Fetal Neonatal Med 2004;15:176-80. -
Platelet changes and subsequent development of pre-eclampsia and fetal growth restriction in women with abnormal uterine artery Doppler screening.
Missfelder-Lobos H, Teran E, Lees C, Albaiges G, Nicolaides KH.
Ultrasound Obstet Gynecol 2002;19:443-8. -
Vasoactive mediator release by fetal endothelial cells in intrauterine growth restriction and preeclampsia.
Parra MC, Lees C, Mann GE, Pearson JD, Nicolaides KH.
Am J Obstet Gynecol 2001;184:497-502.